Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy (Q41624982)

5 October 2017

Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy (English)

1 reference

5 October 2017

4

1 reference

5 October 2017

5

1 reference

5 October 2017

20

1 reference

5 October 2017

Melissa Bersanelli

15

0 references

Alessandro Conti

Alessandro Conti

3

0 references

Sebastiano Buti

Sebastiano Buti

2

0 references

Matteo Santoni

Matteo Santoni

1

0 references

Umberto Basso

Umberto Basso

8

0 references

Stefano Cascinu

Stefano Cascinu

21

0 references

Rodolfo Montironi

19

Rodolfo Montironi

1 reference

5 October 2017

9

Ugo De Giorgi

1 reference

5 October 2017

Cora N Sternberg

6

1 reference

5 October 2017

Sergio Bracarda

7

1 reference

5 October 2017

Mimma Rizzo

10

1 reference

5 October 2017

Lisa Derosa

11

1 reference

5 October 2017

Cinzia Ortega

12

1 reference

5 October 2017

Francesco Massari

13

1 reference

5 October 2017

Michele Milella

14

1 reference

5 October 2017

Linda Cerbone

16

1 reference

5 October 2017

Giovanni Muzzonigro

17

1 reference

5 October 2017

Luciano Burattini

18

1 reference

5 October 2017

6 January 2015

1 reference

5 October 2017

1 reference

5 October 2017

10

1 reference

5 October 2017

517-522

1 reference

5 October 2017

4

1 reference

https://scigraph.springernature.com/pub.10.1007/s11523-014-0356-3

5 October 2017

0 references

cites work

The von Hippel-Lindau tumor suppressor gene and kidney cancer

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0356-3

Heterogeneous drug target expression as possible basis for different clinical and radiological response to the treatment of primary and metastatic renal cell carcinoma: suggestions from bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0356-3

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0356-3

Cancer-related inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0356-3

Neutrophils in the activation and regulation of innate and adaptive immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0356-3

Survival outcome and treatment response of patients with late relapse from renal cell carcinoma in the era of targeted therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0356-3

Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0356-3

Markers of systemic inflammation predict survival in patients with advanced renal cell cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0356-3

The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0356-3

Pre-treatment neutrophil-to-lymphocyte ratio may be associated with the outcome in patients treated with everolimus for metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0356-3

The impact of confounder selection criteria on effect estimation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0356-3

Role of systemic inflammatory response in predicting survival in patients with primary operable cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0356-3

The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0356-3

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0356-3

Hallmarks of Cancer: The Next Generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0356-3

Presence of intratumoral neutrophils is an independent prognostic factor in localized renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0356-3

Validation of serum C-reactive protein (CRP) as an independent prognostic factor for disease-free survival in patients with localised renal cell carcinoma (RCC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0356-3

Validation of CRP as prognostic marker for renal cell carcinoma in a large series of patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0356-3

Validation of the pre-treatment neutrophil-lymphocyte ratio as a prognostic factor in a large European cohort of renal cell carcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0356-3

Prognostic benefit of surgical management in renal cell carcinoma patients with thrombus extending to the renal vein and inferior vena cava: 17-year experience at a single center

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0356-3

The significant immunological characteristics of peripheral blood neutrophil-to-lymphocyte ratio and Fas ligand expression incidence in nephrectomized tumor in late recurrence from renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0356-3

Late recurrence of renal cell carcinoma: retrospective and collaborative study of the Japanese Society of Renal Cancer

21 January 2018

1 reference

12 December 2020

The prognostic significance of immune changes in patients with renal cancer, melanoma and colorectal cancer, treated with interferon alpha 2b

1 reference

12 December 2020

Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma.

1 reference

12 December 2020

Changes in lymphocyte count induced by repeated cycles with low-dose interleukin-2 and interferon-α in 146 patients with renal cell carcinoma.

1 reference

12 December 2020

Renal cell carcinoma: long-term survival and late recurrence

1 reference

12 December 2020

Late recurrence of renal cell carcinoma after nephrectomy

1 reference

12 December 2020

Multinomial goodness-of-fit tests for logistic regression models

1 reference

12 December 2020

Pretreatment neutrophil-to-lymphocyte ratio as an independent predictor of recurrence in patients with nonmetastatic renal cell carcinoma

1 reference

12 December 2020

Followup of neutrophil-to-lymphocyte ratio and recurrence of clear cell renal cell carcinoma

1 reference

12 December 2020

Changes in peripheral blood immune cells: their prognostic significance in metastatic renal cell carcinoma patients treated with molecular targeted therapy

1 reference

12 December 2020

10.1007/S11523-014-0356-3

Identifiers

DOI

1 reference

5 October 2017

1 reference